However, the clinical success rate for BTK inhibitors in RA has been relatively poor compared to the promising results of BAFF and APRIL-targeted therapies, which have generally shown better efficacy across multiple autoimmune diseases (208). The gene discussed is TNFSF13B; the disease is autoimmune disease.